Comparison · NCT00130728-sae
Erlotinib HCl + Bevacizumab vs Erlotinib HCl + Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Erlotinib HCl + Bevacizumab vs Erlotinib HCl + Placebo: serious adverse events. Trial comparisons, record NCT00130728-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00130728-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.466 | 0.412 | 0.522 | wilson | |
| Risk in group 2 | 0.387 | 0.334 | 0.442 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0799 | 0.00242 | 0.156 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 1 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 1.01 | 1.91 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Erlotinib HCl + Bevacizumab than on Erlotinib HCl + Placebo | 12.5 | 6.41 | 414 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Erlotinib HCl + Bevacizumab | oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle | 146 | 313 | EG000 |
| Group 2 | Erlotinib HCl + Placebo | oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle | 121 | 313 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From randomization to up to 3.8 years (for Adverse Events) From randomization until last patient last visit or up to 14.5 years from start of study (for Serious Adverse Events)
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
- NCT number
- NCT00130728
- Phases
- PHASE3
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- bevacizumab, erlotinib HCl, placebo
- Lead sponsor
- Genentech, Inc.
- Results first posted
- 2011-11-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00130728?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00130728-sae